Warning: The NCBI web site requires JavaScript to function. more...
Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada.
Blackhouse G, Gaebel K, Xie F, Campbell K, Assasi N, Tarride JE, O'Reilly D, Chalk C, Levine M, Goeree R.
Cost Eff Resour Alloc. 2010 Jun 17;8:14.
Related citations
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J, Jones J, Takeda A, Davidson P, Price A.
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.
Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
Xie F, Blackhouse G, Assasi N, Campbell K, Levin M, Bowen J, Tarride JE, Pi D, Goeree R.
Clin Ther. 2009 May;31(5):1082-91; discussion 1066-8.
Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy.
McCrone P, Chisholm D, Knapp M, Hughes R, Comi G, Dalakas MC, Illa I, Kilindireas C, Nobile-Orazio E, Swan A, Van den Bergh P, Willison HJ; INCAT Study Group.
Eur J Neurol. 2003 Nov;10(6):687-94.
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.
Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.
Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.
Hahn AF, Bolton CF, Zochodne D, Feasby TE.
Brain. 1996 Aug;119 ( Pt 4):1067-77.
Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.
Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN.
Cochrane Database Syst Rev. 2009 Jan 21;(1):CD001797. Review.
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.
Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.
Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial.
Hughes RA.
Expert Rev Neurother. 2009 Jun;9(6):789-95. Review.
Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.
Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.
Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
Tunis SL, Sauriol L, Minshall ME.
Appl Health Econ Health Policy. 2010;8(4):267-80. doi: 10.2165/11535380-000000000-00000.
Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy.
van Doorn PA.
J Neurol Neurosurg Psychiatry. 1994 Nov;57 Suppl:38-42. Review.
Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.
Blackhouse G, Assasi N, Xie F, Marshall J, Irvine EJ, Gaebel K, Campbell K, Hopkins R, O'Reilly D, Tarride JE, Goeree R.
J Crohns Colitis. 2012 Feb;6(1):77-85. Epub 2011 Sep 9.
The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.
Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.
Long-term effects of intravenous immunoglobulin in CIDP.
Vucic S, Black K, Baldassari LE, Tick Chong PS, Dawson KT, Cros D.
Clin Neurophysiol. 2007 Sep;118(9):1980-4. Epub 2007 Jun 28.
Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy.
Tackenberg B, Nimmerjahn F, Lünemann JD.
J Clin Immunol. 2010 May;30 Suppl 1:S65-9. Review.
Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
Hughes RA, Gorson KC, Cros D, Griffin J, Pollard J, Vallat JM, Maurer SL, Riester K, Davar G, Dawson K, Sandrock A; Avonex CIDP Study Group.
Neurology. 2010 Feb 23;74(8):651-7.
Inflammatory demyelinating neuropathies.
Muley SA, Parry GJ.
Curr Treat Options Neurol. 2009 May;11(3):221-7.
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.
Health Technol Assess. 2008 Apr;12(11):1-278, iii. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on